Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Renal Insufficiency, Chronic 1Non-alcoholic Fatty Liver Disease 1Liver Cirrhosis, Alcoholic 1Hypothermia 1Hepatitis C 1Hepatitis B 1Fibrosis 1End Stage Liver Disease 1Carcinoma, Hepatocellular 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hypothermia, Induced × Clear all
NCT03534141 2025-05-16

MHALT

University of California, San Francisco

Phase NA Terminated
175 enrolled 19 charts
GastrointestinalGenitourinary

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Hypothermia, Liver Cirrhosis, Alcoholic, Renal Insufficiency, Chronic, Acute Kidney Injury, End Stage Liver Disease, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡